Could the Combination of a Personalized Neoantigen-Specific T-Cell Therapy & a Personalized Cancer-Vaccine Alleviate Some of the Potency Problems with Cancer Vaccines?
4:00 pm - Wednesday 2nd December 2026
- We have developed SeqCureNEO to make a T-cell therapy with full control over specificity, potency and therapeutic dose
- Currently cancer vaccines have only shown promise in the setting of minimal residual disease and vaccine responses are commonly only seen to a few of the neoantigen epitopes
- We propose combining SeqCureNEO with a cancer vaccine based on the same neoepitopes. Why such a combination would create more potent clinical responses will be discussed in the talk
